Eris Lifesciences Eyes Strategic Stake In Swiss Parenterals To Expand Injectables Portfolio

Eris Lifesciences Ltd, a leading player in India’s branded formulations market, has announced its intent to consider acquiring a stake in Swiss Parenterals, a Gujarat-based manufacturer of sterile injectable products. The proposed transaction is part of Eris’s broader strategy to expand its footprint in the high-growth injectables segment and enhance its institutional business.

Swiss Parenterals operates multiple manufacturing facilities compliant with global regulatory standards and exports to over 60 countries. The potential investment would provide Eris with access to a diversified product pipeline and international markets.

Key highlights from the announcement include:  

• The board of Eris Lifesciences will evaluate the proposed acquisition in an upcoming meeting.
• Swiss Parenterals specializes in sterile injectables, lyophilized products, and ophthalmic formulations.
• The deal aligns with Eris’s focus on expanding its hospital and critical care portfolio.
• Eris has been actively pursuing inorganic growth, having completed multiple acquisitions in recent years.
• The transaction, if approved, could enhance Eris’s export capabilities and manufacturing scale.

Sources: Reuters, Eris Lifesciences Ltd Exchange Filings, Swiss Parenterals Corporate Profile, Business Standard.